The ZNF200 antibody is a tool used to detect and study the zinc finger protein 200 (ZNF200), a member of the Krüppel-associated box (KRAB) domain-containing zinc finger protein (ZNF) family. ZNF200. encoded by the human ZNF200 gene, is characterized by its N-terminal KRAB domain and multiple C-terminal C2H2-type zinc finger motifs, which are critical for DNA binding and protein-protein interactions. As a transcription regulator, ZNF200 is implicated in chromatin remodeling and transcriptional repression, potentially through interactions with histone deacetylases (HDACs) or other chromatin-modifying complexes. Its expression has been observed in various tissues, though functional studies remain limited compared to other ZNF proteins.
Research involving ZNF200 antibodies primarily focuses on elucidating its role in cellular processes, including differentiation, apoptosis, and tumor suppression. Some studies suggest ZNF200 may act as a tumor suppressor in certain cancers, such as leukemia, by modulating oncogenic pathways. Additionally, its potential involvement in neurodegenerative diseases, like Parkinson’s, has been explored due to links with oxidative stress responses. The antibody is commonly utilized in techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess protein expression levels, subcellular localization, and interaction partners.
Despite its utility, challenges persist in specificity and availability of high-quality ZNF200 antibodies, partly due to the protein’s low abundance and structural homology with other ZNF family members. Ongoing research aims to clarify its mechanistic roles and therapeutic relevance.